

[First Hit](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)**End of Result Set**☐ [Generate Collection](#) [Print](#)

L3: Entry 1 of 1

File: DWPI

Feb 1, 1995

DERWENT-ACC-NO: 1995-054394

DERWENT-WEEK: 199749

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Prepn. of edible water-in-oil emulsions contg. fish oil and ascorbyl palmitate - using aq. phase prepd. without using components which react with or act as catalyst for reaction with ascorbyl palmitate

INVENTOR: MAGUIRE, J ; MCAULIFFE, J P

PATENT-ASSIGNEE:

ASSIGNEE

CODE

CHARLEVILLE RES LTD

CHARN

PRIORITY-DATA: 1993IE-0000497 (July 2, 1993), 1994WO-IE00061 (December 22, 1994), 1995AU-0013269 (December 22, 1994)

☐ [Search Selected](#)☐ [Search ALL](#)☐ [Clear](#)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <u>GB 2280449 A</u>	February 1, 1995		019	A23D007/00
<input type="checkbox"/> <u>IE 76129 B</u>	October 8, 1997		000	A23D007/02
<input type="checkbox"/> <u>IE 62576 B3</u>	February 8, 1995		000	A23C021/00
<input type="checkbox"/> <u>WO 9619114 A1</u>	June 27, 1996	E	037	A23D007/00
<input type="checkbox"/> <u>AU 9513269 A</u>	July 10, 1996		000	A23D007/00
<input type="checkbox"/> <u>GB 2280449 B</u>	October 2, 1996		000	A23D007/00

DESIGNATED-STATES: AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN AT BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT SD SE SZ

CITED-DOCUMENTS: 1.Jnl.Ref ; EP 304115 ; GB 2280449 ; US 4764392 ; WO 8902223 ; WO 9506414

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
GB 2280449A	July 4, 1994	1994GB-0013405	
IE 76129B	July 1, 1994	1994IE-0000534	
IE 62576B3	July 1, 1994	1994IE-0000535	
WO 9619114A1	December 22, 1994	1994WO-IE00061	

AU 9513269A	December 22, 1994	1994WO-IE00061	
AU 9513269A	December 22, 1994	1995AU-0013269	
AU 9513269A		WO 9619114	Based on
GB 2280449B	July 4, 1994	1994GB-0013405	

INT-CL (IPC): A23C 21/00; A23C 23/00; A23D 7/00; A23D 7/02; A23D 7/06

ABSTRACTED-PUB-NO: GB 2280449A

BASIC-ABSTRACT:

Prepn. of edible water-in-oil (w/o) emulsion comprising fish oil contg. ascorbyl palmitate (I) as an antioxidant, and an aq. phase, involves using an aq. phase contg. no ingredients or additives that either react with or catalyse the reaction of (I). Also claimed is the emulsion and a spread prepd. from the emulsion.

The aq. phase pref. does not contain whey, skimmed milk, buttermilk and/or whole milk, all opt. in powder form, or Na caseinate. It is prepd. with deionised water. It contains a sequestrant to bind metal ions. The sequestrant is citric acid or its salts, EDTA or its salts and/or phosphate salts. The fat phase also contains a vegetable oil, esp. a room temp. liq. oil. The oil is rapeseed, soybean, sunflower or olive oil. The fat phase is a hard stock oil, solid at room temp., esp. a vegetable oil, esp. a (partially) hydrogenated soybean, rapeseed, palm, coconut or palm kernel oil, a naturally hard vegetable oil or an animal fat. It contains an emulsifier, esp. mono- or di-glyceride. It contains colouring, flavouring and/or vitamins. The aq. phase contains lactic acid, protein and/or flavouring.

USE - The emulsions are for administration of omega-3 polyunsatd. fatty acids for protection against heart disease. They may be taken in margarine form.

ADVANTAGE - Metallic off-flavours and fish tastes are prevented or at least their development is retarded.

ABSTRACTED-PUB-NO:

GB 2280449B

EQUIVALENT-ABSTRACTS:

A method for preparing an edible water-in-oil emulsion comprising fish oil, the water-in-oil emulsion comprising a fat phase and an aqueous phase, the fat phase comprising fish oil containing an antioxidant including ascorbyl palmitate, wherein the aqueous phase is prepared without ingredients or additives which may react with or act as a catalyst for a reaction with, ascorbyl palmitate to at least retard the development of a metallic type off-flavour or fishy taste.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: PREPARATION EDIBLE WATER OIL EMULSION CONTAIN FISH OIL ASCORBYL PALMITATE AQUEOUS PHASE PREPARATION COMPONENT REACT ACT CATALYST REACT ASCORBYL PALMITATE

ADDL-INDEXING-TERMS:

HEART DISEASE PROTECTION

DERWENT-CLASS: D13

CPI-CODES: D03-C02;

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0419U ; 1662U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1995-024671

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)☐ [Generate Collection](#)[Print](#)

L1: Entry 1 of 2

File: DWPI

Oct 24, 2002

DERWENT-ACC-NO: 2003-219905

DERWENT-WEEK: 200321

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: New phytosterol and/or phytostanol and ascorbic acid containing derivatives useful in treating e.g. cardiovascular disease

INVENTOR: CHEN, H ; DING, Y ; HOU, D ; KUTNEY, J P ; MILANOVA, R K

PATENT-ASSIGNEE:

ASSIGNEE

CODE

FORBES MEDI-TECH INC

FORBN

PRIORITY-DATA: 2001US-0916817 (July 25, 2001), 1999US-0339903 (June 23, 1999)

[Search Selected](#)[Search ALL](#)[Clear](#)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <u>US 20020156051 A1</u>	October 24, 2002		035	A61K031/665

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
US20020156051A1	June 23, 1999	1999US-0339903	CIP of
US20020156051A1	July 25, 2001	2001US-0916817	

INT-CL (IPC): A61K 31/585; A61K 31/665; C07J 1/00; C07J 17/00

RELATED-ACC-NO: 2001-112435

ABSTRACTED-PUB-NO: US20020156051A

BASIC-ABSTRACT:

NOVELTY - Phytosterol and/or phytostanol and ascorbic acid containing derivatives (I) - (III) are new.

DETAILED DESCRIPTION - Phytosterol and/or phytostanol and ascorbic acid derivatives of formula R2P(O)(OR3)OR (I), R2C(O)OR (II) or R2C(O)C(O)OR (III) and their salts are new.

R = phytosterol or phytostanol selected from sitosterol, campesterol, stigmasterol, brassicasterol, desmosterol, chalinosterol, poriferasterol, clionasterol, sitostanol, campestanol, stigmastanol, brassicastanol, desmostanol, chalinostanol, poriferastanol or clionastanol (preferably sitostanol or campestanol);

R2 = ascorbic acid; and

R3 = H, alkali earth metal or alkali metal.

ACTIVITY - Cardiant; Antiarteriosclerotic; Antilipemic; Hypotensive; Thrombolytic; Antidiabetic; Nootropic; Cytostatic.

MECHANISM OF ACTION - None given.

USE - In the treatment or prevention of cardiovascular disease, conditions including atherosclerosis or hyperlipidemia (claimed). Also useful in treating hypercholesterolemia, hypertension, thrombosis, related diseases (e.g. Type II diabetes), other diseases including oxidative damage (e.g. dementia, aging or cancer); in food and beverages.

ADVANTAGE - The compounds have additive and synergistic effect both in lowering serum cholesterol and as an anti-oxidant between the phytosterol/stanol or ascorbic acid. The solubility of derivative is greatly enhanced, both in aqueous solutions and non-aqueous media such as oil and fat. Therefore, greater solubility, effective dietary and therapeutic dosages and costs may be reduced.

CHOSEN-DRAWING: Dwg.0/18

TITLE-TERMS: NEW PHYTOSTEROL ASCORBIC ACID CONTAIN DERIVATIVE USEFUL TREAT CARDIOVASCULAR DISEASE

DERWENT-CLASS: B01 D13

CPI-CODES: B01-D01; B01-D02; B03-F; B05-B01M; B05-B01P; B14-F01; B14-F02B; B14-F04; B14-F06; B14-F07; B14-H01B; B14-J01; B14-S04; B14-S08; D03-H01G; D03-H01T2;

CHEMICAL-CODES:

Chemical Indexing M5 *01*

Fragmentation Code

M431 M782 M904 M905 P440 P450 P522 P526 P631 P813

P814 P816 Q110 Q620 Q624

Specific Compounds

11100K 11100T 11100Q 11100M

Chemical Indexing M5 *02*

Fragmentation Code

M431 M782 M904 M905 P440 P450 P522 P526 P631 P813

P814 P816 Q110 Q620 Q624

Specific Compounds

A0N0JK A0N0JT A0N0JQ A0N0JM

Chemical Indexing M5 *03*

Fragmentation Code

M431 M782 M904 M905 P440 P450 P522 P526 P631 P813

P814 P816 Q110 Q620 Q624

Specific Compounds

13235K 13235T 13235Q 13235M 15106K 15106T 15106Q 15106M

Chemical Indexing M5 *04*

Fragmentation Code

M431 M782 M904 M905 P440 P450 P522 P526 P631 P813

P814 P816 Q110 Q620 Q624

Specific Compounds
A0P8EK A0P8ET A0P8EQ A0P8EM

Chemical Indexing M5 *05*

Fragmentation Code
M431 M782 M904 M905 M910 P440 P450 P522 P526 P631
P813 P814 P816 Q110 Q620 Q624
Specific Compounds
01434K 01434T 01434Q 01434M
Registry Numbers
1434S 1434U

Chemical Indexing M5 *06*

Fragmentation Code
M431 M782 M904 M905 M910 P440 P450 P522 P526 P631
P813 P814 P816 Q110 Q620 Q624
Specific Compounds
00499K 00499T 00499Q 00499M
Registry Numbers
0499S 0499U

Chemical Indexing M5 *07*

Fragmentation Code
M431 M782 M904 M905 P440 P450 P522 P526 P631 P813
P814 P816 Q110 Q620 Q624
Specific Compounds
A0F4JK A0F4JT A0F4JQ A0F4JM

Chemical Indexing M5 *08*

Fragmentation Code
M431 M782 M904 M905 P440 P450 P522 P526 P631 P813
P814 P816 Q110 Q620 Q624
Specific Compounds
A0F4IK A0F4IT A0F4IQ A0F4IM

Chemical Indexing M5 *09*

Fragmentation Code
M431 M782 M904 M905 M910 P440 P450 P522 P526 P631
P813 P814 P816 Q110 Q620 Q624
Specific Compounds
00498K 00498T 00498Q 00498M
Registry Numbers
0498S 0498U

Chemical Indexing M5 *10*

Fragmentation Code
M417 M431 M782 M904 M905 P440 P450 P522 P526 P631
P813 P814 P816 Q110 Q620 Q624
Specific Compounds
A012OK A012OT A012OQ A012OM

Chemical Indexing M5 *11*

Fragmentation Code
M431 M782 M904 M905 P440 P450 P522 P526 P631 P813
P814 P816 Q110 Q620 Q624
Markush Compounds
200087-51801-K 200087-51801-T 200087-51801-Q 200087-51801-M

Chemical Indexing M2 *12*

Fragmentation Code

F012 F013 F014 F015 F113 H4 H403 H421 H482 H8
J5 J522 K0 L8 L818 L821 L832 L9 L942 L960
M280 M312 M321 M332 M343 M373 M391 M413 M431 M510
M521 M530 M540 M782 M904 M905 M910 P440 P450 P522
P526 P631 P813 P814 P816 Q110 Q620 Q624
Specific Compounds
00035K 00035T 00035Q 00035M 04454K 04454T 04454Q 04454M
Registry Numbers
0035S 0035U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0035S ; 0035U ; 0498S ; 0498U ; 0499S ; 0499U ;
1434S ; 1434U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2003-055831

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L4: Entry 1 of 2

File: DWPI

Oct 18, 2001

DERWENT-ACC-NO: 2002-040630

DERWENT-WEEK: 200205

COPYRIGHT 2007 DERWENT INFORMATION LTD

TITLE: Composition useful for treating a disorder such as adult respiratory distress syndrome in a mammal comprises sesamol or its metabolite

INVENTOR: CHAVALI, S R ; FORSE, R A

PATENT-ASSIGNEE:

ASSIGNEE

CODE

CHAVALI S R

CHAVI

FORSE R A

FORSI

PRIORITY-DATA: 2000US-0483630 (January 14, 2000), 1998US-0020550 (February 9, 1998)

[Search Selected](#)[Search ALL](#)[Clear](#)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

US 20010031275 A1

October 18, 2001

011

A23L001/30

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

US20010031275A1

February 9, 1998

1998US-0020550

CIP of

US20010031275A1

January 14, 2000

2000US-0483630

INT-CL (IPC): A01N 43/30; A01N 65/00; A23K 1/175; A23L 1/28; A23L 1/30; A61K 31/36; A61K 47/00; B09B 3/00

RELATED-ACC-NO: 2001-167742

ABSTRACTED-PUB-NO: US20010031275A

BASIC-ABSTRACT:

NOVELTY - A composition comprises sesamol or its metabolite.

ACTIVITY - Nootropic; neuroprotective; antiarthritic; antibacterial; antiarteriosclerotic; cytostatic; antipyretic; immunosuppressive; antiinflammatory.

MECHANISM OF ACTION - Delta -5-Desaturase inhibitor, arachidonic acid metabolism inhibitor, arachidonic acid metabolite inhibitor, PGE2 (endotoxin-induced prostaglandin) inhibitor, PLA2 inhibitor, IL-12 inhibitor, IL-10 (interleukin-12, -

6 and -10) inhibitor; TNF (tumor necrosis factor)- alpha inhibitor (all claimed).

The sesamol inhibits Delta -5 desaturase activity and also decreasing the production of prostaglandin PGE2. Thus the effects for the synthetic pure form of sesamol on proinflammatory immune responses during septic shock were studied. Female Balb/c mice were fed diets supplemented with safflower oil (SO) (5%) in the absence (i.e. control) or presence of 0.25% synthetic sesamol (i.e. test) for 3 weeks. After a challenge with LPS (50 micro g/mouse) for 90 minute, or 3 hours, the plasma levels (pg/ml) of interleukin (IL-6), IL-10, IL-12, tumor necrosis factor (TNF)- alpha and PGE2 were determined. The results showed 360 plus or minus 32/418 plus or minus 51 for IL-6, 490 plus or minus 35 (the level of significance (p) less than 0.05)/314 plus or minus 37 for IL-10, 8,969 plus or minus 725 (p less than 0.05)/11,165 plus or minus 549 for IL-12, 4,503 plus or minus 478 (p = less than 0.05)/9,497 plus or minus 1425 for TNF- alpha , and 265 plus or minus 39 (p = less than 0.05)/595 plus or minus 68 for PGE2 respectively. This result showed that sesamol caused an increase in the secretion of anti-inflammatory cytokines (e.g. IL-10) and a reduction in the formation of proinflammatory mediators (e.g. IL-12, TNF- alpha and PGE2) during endotoxic shock.

USE - As an anti-inflammatory agent, dietary supplement, nutritional supplement or medical food e.g. nutritional beverage, baked good e.g. cookie, brownie, fudge, cake, bread, biscuit and cracker), pudding, confection, snack food, ice cream, frozen confection, and non-baked, extruded food product (e.g. extruded bar) for treating a disorder such as adult respiratory distress syndrome, Alzheimer's disease, arthritis, lyme disease, atherosclerosis, cardiovascular disease, aging, breast cancer, head cancer, neck cancer, flu and sepsis; to treat inflammation; for inhibiting inflammation, Delta -5-desaturase activity, arachidonic acid metabolism, the formation of arachidonic acid, metabolites, level of PGE2 (endotoxin-induced prostaglandin), activity of PLA2, the level of IL-12 (interleukin-12), the level of TNF- alpha (tumor necrosis factor- alpha), the level of IL-10 in a mammal (all claimed) such as primate (e.g. human), dog, cat, cow, horse, pig or goat.

ADVANTAGE - The composition improves the functions of vital organs such as heart, lungs, liver and kidneys. The levels of TNF, a proinflammatory mediator are not elevated in mice fed sesamol in compared to TNF levels with other anti-inflammatory agents such as sesamin. The sesamol does not induce the undesirable side effects induced by many anti-inflammatory agents.

CHOSEN-DRAWING: Dwg.0/3

TITLE-TERMS: COMPOSITION USEFUL TREAT DISORDER ADULT RESPIRATION DISTRESS SYNDROME MAMMAL COMPRISE SESAMOL METABOLITE

DERWENT-CLASS: B02 D13 P43

CPI-CODES: B03-L; B04-B01B; B06-A02; B14-A01; B14-A02B2; B14-B04A; B14-C03; B14-C09; B14-D03; B14-F01; B14-F02; B14-F07; B14-H01; B14-J01A4; B14-K01F; B14-L06; B14-L08; D03-H01T;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
M423 M431 M782 M905
Specific Compounds
A01IKK A01IKM

Chemical Indexing M1 *02*
Fragmentation Code

M423 M431 M782 M905
Specfic Compounds
A00GTK A00GTM

Chemical Indexing M2 *03*

Fragmentation Code

D022 D140 H4 H401 H441 H8 M280 M320 M412 M431
M511 M520 M530 M540 M782 M904 M905 P210 P220 P330
P420 P421 P446 P520 P522 P616 P617 P625 P633 P814
P820 Q220

Specfic Compounds

09687K 09687T 09687M

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C2002-011503

Non-CPI Secondary Accession Numbers: N2002-030108

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)